NCT00001576View on ClinicalTrials.gov

A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 1997

Study Completion Date

March 31, 2002

Conditions

Colorectal NeoplasmLiver NeoplasmNeoplasm Metastasis

Interventions

DRUG

Melphalan

DRUG

Floxuridine

DRUG

Leucovorin

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00001576 - A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver | Biotech Hunter | Biotech Hunter